Jefferies analyst Tycho Peterson raised the firm’s price target on Quest Diagnostics (DGX) to $220 from $215 and keeps a Buy rating on the shares. Quest Diagnostic’s quarterly results beat on revenues and earnings peer share, with FY26 beating by +3% and implying 6-7% growth, the analyst tells investors in a research note. The firm added that the quarter and guidance beats are an encouraging start to 2026, as it sees solid growth optionality ahead.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Early notable gainers among liquid option names on February 10th
- Morning Movers: Fiserv and Spotify jump following fourth quarter results
- Quest Diagnostics Posts Strong 2025 Results, Boosts Shareholder Returns
- Quest Diagnostics reports Q4 adjusted EPS $2.42, consensus $2.36
- Quest Diagnostics sees FY26 adjusted EPS $10.50-$10.70, consensus $10.42